These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27093208)

  • 21. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Verma S; Bhatt DL; Bain SC; Buse JB; Mann JFE; Marso SP; Nauck MA; Poulter NR; Pratley RE; Zinman B; Michelsen MM; Monk Fries T; Rasmussen S; Leiter LA;
    Circulation; 2018 May; 137(20):2179-2183. PubMed ID: 29760228
    [No Abstract]   [Full Text] [Related]  

  • 23. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
    Urakami T; Habu M; Okuno M; Suzuki J; Takahashi S; Yorifuji T
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):327-31. PubMed ID: 25332292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 26. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
    Doggrell SA
    Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of the LEADER study: current evidence and perspectives in research].
    Mannucci E
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
    Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
    Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
    [No Abstract]   [Full Text] [Related]  

  • 34. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
    Kaneko S; Ueda Y; Tahara Y
    Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardiovascular risk reduction in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
    Consoli A; Di Fulvio P
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):21S-26S. PubMed ID: 25623547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.
    Herzlinger S; Horton ES
    Diabetes Res Clin Pract; 2013 Apr; 100(1):1-10. PubMed ID: 23332049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Spellman CW
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
    Russo GT; Labate AM; Giandalia A; Romeo EL; Villari P; Alibrandi A; Perdichizzi G; Cucinotta D
    J Endocrinol Invest; 2015 Jan; 38(1):81-9. PubMed ID: 25173876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.